Expanded collaboration between Inventage Lab and Boehringer Ingelheim on long-acting formulations research

[by Ji, Yong Jun] Inventage Lab has continued to advance its partnership with the global pharmaceutical company Boehringer Ingelheim to develop long-acting injectable therapeutics utilizing peptide-based drug candidates. Building upon the initial joint research agreement established in September 2024, the two companies have now entered into an expanded agreement for additional drug candidates.

Inventage Lab announced on November 21 that it has entered into an additional joint research agreement with Boehringer Ingelheim to advance the development of peptide-based long-acting injectable formulations. The companies agreed not to disclose the upfront payment associated with the contract.

Under the new agreement, the two companies will continue collaborative research aimed at developing Boehringer Ingelheim's peptide drug candidates into long-acting injectable formulations by utilizing Inventage Lab's proprietary microfluidic formulation platform, IVL-DrugFluidic. According to both parties, this expanded collaboration follows the positive outcomes from the initial joint research agreement concluded in September of last year.

In the initial phase of joint research, Inventage Lab successfully transformed Boehringer Ingelheim's peptide drug into a stable and uniform long-acting formulation through the application of its microfluidic formulation technology. The company also reported favorable outcomes in major technical parameters, including sustained therapeutic efficacy and controlled in-vivo release. As a result, Boehringer Ingelheim is said to be pursuing this additional agreement to extend the application of the technology to further peptide candidates.

Through this collaboration, Inventage Lab has broadened the application scope of its technology and further reinforced its partnership with a global pharmaceutical company. The additional agreement is regarded as a significant milestone in the ongoing process of technology validation and commercialization with global pharmaceutical partners. In light of the growing market attention surrounding long-acting injectables, the company is currently engaged in active discussions regarding concrete collaboration opportunities with major global pharmaceutical and biotechnology firms.

Inventage Lab noted that the additional agreement not only reinforces the research achievements of its existing joint research pipeline but also substantially increases the prospects for future out-licensing (technology transfer) opportunities. “This additional contract was first proposed by Boehringer Ingelheim, serving as yet another validation case of the credibility of our technology and the business potential of our company,” said Kim Ju-hee, CEO of Inventage Lab. “Building on our robust partnership with Boehringer Ingelheim, we intend to achieve commercialization outcomes within a short timeframe and accelerate the global commercialization of long-acting formulation technology,” she added.